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Abstract 
A series of 2,5,7-trisubstituted pyrimido[4,5-d]pyrimidine cyclin-dependent 
kinase (CDK2) inhibitors is designed and synthesized. 6-Amino-2-thiouracil is 
reacted with an aldehyde and thiourea  to prepare the pyrimido[4,5-d]-
pyrimidines. Alkylation and amination of the latter ones give  different amino 
derivatives. These compounds show potent and selective CDK inhibitory 
activities and inhibit in vitro cellular proliferation in cultured human tumor cells.  
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Introduction 
Conventional anti-cancer drugs such as alkylating agents, antimetabolites, topoisomerase 
inhibitors, and anti-microtubule agents have traditionally focused on targeting DNA 
synthesis and cell division. Although these drugs show efficacy, their lack of selectivity for 
tumor cells over normal cells usually lead to severe adverse effects such as bone marrow 430  S. M. El-Moghazy et al.:   
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suppression, cardiac, hepatic, and renal toxicities which limit their use. In an attempt to 
circumvent these unpleasant side effects, a new class of anti-cancer agents known as 
signal transduction or secondary message inhibitors has been developed [1]. Cells use a 
wide variety of both intra- and intercellular mechanisms to signal for processes including 
growth, apoptosis, and intracellular protein degradation. Due to up-regulation or greater 
dependence on some of these pathways in tumor cells, inhibition should lead to anti-
cancer effects [2]. 
The D-type cyclins and their kinase partners (CDKs) have an important role in cell cycle as 
they phosphorylate the tumor suppressor protein, retinoblastoma protein (PRB) during the 
G-1 phase of the cell cycle and contribute in its inactivation. They also act as integrators of 
extracellular signals. Specific CDKs operate in distinct phases of the cell cycle e.g. 
CDK4/CyclinD and CDK6/CyclinD are responsible for the progression through the G1 
phase, CDK2/CyclinE is required for the progression from G1 phase to S, CDK2/ CyclinA 
is required for the transition through S, while CDK1/CyclinB is required for the G2/M 
transition  [1–4]. These CDK-cyclin complexes are in turn regulated by small inhibitory 
proteins called Endogenous CDK inhibitors. 
Pyrimidopyrimidines are annelated uracils that have attracted considerable interest in 
recent years  [5, 6]. Their  derivatives have been known to display a wide range of 
pharmacological activities, and their potent inhibitory properties regarding the tyrosine 
kinase domain of epidermal growth factor receptor [7], 5-phosphoribosyl-1-pyrophosphate 
synthetase [8] and dihydrofolate reductase [9] have been fully demonstrated. Numerous 
reports delineate the anti-tumour [10], antiviral [10, 11], antioxidant [12], antifungal [13] and 
hepatoprotective activities of these compounds [14]. 
In our program to develop CDK2 inhibitors as anti-cancer agents, we recently reported that 
pyrazolo[3,4-d]pyrimidines and 3,6-disubstituted [1,2,4]triazolo[3,4-b][1,3,4]thiadiazole 
analogs are novel anti-cancer inhibitors and anti-proliferative agents [15, 16]. To discover 
structurally different CDK2 inhibitors with improved potency and selectivity, we have 
designed, synthesized, and evaluated trisubstituted pyrimido[4,5-d]pyrimidines as 
inhibitors of tumor cell proliferation. 
Results and Discussion 
Rational and design 
We have been interested in developing inhibitors of CDK2, and the crystal structure of the 
kinases domain has been solved by X-ray crystallography. These targets therefore were 
not only amenable to hit discovery by virtual screening techniques but also suited to show 
our pharmacophore models to design a new lead compounds that can act as CDK2 
inhibitors with reasonable selectivity.  We selected pyrimido[4,5-d]pyrimidine moiety to 
mimic the adenine region at ATP binding site and according to modeling results we 
optimized the side chains to improve the activity and selectivity.  
Preparation of the designed structure 
The coordinate for the protein structure was obtained from the RCSB Protein Data Bank 
(PDB) (1ke6) [17]. Protein Structure was prepared using Discovery Studio (DS 2.0) 
software package [18]. The invalid or missing residues were added and the structures   Design, Synthesis and Biological Evaluation of Novel Pyrimido[4,5-d]pyrimidine CDK2 Inhibitors …  431 
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were aligned using the protein structure alignment module. Hydrogen atoms were added 
and the structure was minimized using CHARMm force field to relax the backbone and to 
remove the clashes. The protein was inspected visually for accuracy in the X2 dihedral 
angle of Asn, His residues and the X3 angle of Gln. 
The proposed compounds were optimized by semiemperical method (AM1) using 
Chem3D to eliminate bond length and bond angle biases then saved to be used in the 
pharmacophore mapping step. 
Pharmacophore Generation  
Two pharmacophore models were generated. The first was more accurate specific cyclin-
dependant kinase pharmacophore model and derived from the PDB (1ke6) crystal 
structure. We defined the active pocket features (all hydrogen bond donors, acceptors and 
hydrophobic centers) and according to these features we estimate the first pharmacophore 
model. In this pharmacophore model (Fig 1) a donor atom associated with the protein 
donor site is used to donate the key hydrogen bond interaction. 
 
Fig. 1.   Pharmacophore model (1) derived from CDK2 crystal structure (PDB code: 
1ke6) (Green, acceptor atom; Magenta, donor atom, Cyan, hydrophobic 
centers) 
The second pharmacophore model was derived from 7 potent inhibitors (Fig 2) of CDK2 by 
calculating the common features protocol. This model was made up of hydrophobic center, 
aromatic ring, acceptor atom associated to its protein donor site and donor atom (Fig 3).  
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The interfeature distances were considered to be 7.61, 6.50, 4.24, 8.69 and 5.4 A° for the 
distances between the aromatic center and the donor 1, the aromatic center and the 
acceptor, the acceptor and hydrophobe, the hydrophobe and the donor 2, and the donor 2 
to donor 1, respectively. The association of the acceptor atom to the donor site in the 
protein ensured the overall orientation of the molecules with respect to the kinase. Only 
one angle constraint was used for the hydrophobic and the acceptor atom features, thus 
allowing the hydrophobic and the aromatic centers to cover the large domain in the kinase 
active site, from the hydrophobic to the sugar pocket. Since not all proposed compounds 
place hydrophobes in both regions, a partial match directive was used on the query for the 
hydrophobic centers to match compounds that contain only one. We built the first 
pharmacophore model to ensure that proposed compounds with different interaction 
modes (different from interaction modes of compounds in Fig 2) will  be taken in 
consideration in this model.  
 
Fig. 3.   Pharmacophore model 2, which derived from potential CDK2 inhibitors and 
used in the pre-selection of the proposed compounds (Hydr, hydrophobic 
center; HBA, acceptor atom; HBD, donor atom; Aromatic, aromatic center). 
Using these pharmacophore models, we mapped our proposed compounds which contain 
pyrimido[4,5-d]pyrimidine moiety to the generated pharmacophore models in order to find 
the promising compounds that are capable of binding to CDK2 with a similar set of 
interactions (Figs 4 and 5). Finally, we selected the proposed compounds with high fit 
values for synthesis. 
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Fig. 4.   Mapping of compound 7f to pharmacophore 1 (Fit value = 4.1) 
 
Fig. 5.   Mapping of compound 7f to pharmacophore 2 (Fit value = 2.95) 
Chemistry 
Pietro Biginelli reported the first synthesis of 3,4-dihydropyrimidin-2(1H)-ones by a very 
simple one-pot condensation reaction of aromatic aldehyde, urea and ethyl acetoacetate in 
ethanolic solution [19] and as a new modification we prepared pyrimido[4,5-d]pyrimidine 
derivatives by using 6-amino thiouracil derivative, aldehydes and guanidine derivatives. 
The best reaction product was achieved by using glacial acetic acid as a solvent. 
The newly synthesized compounds were prepared as outlined in Scheme 1; Compound 1 
was prepared by the reaction of thiourea with ethyl cyanoacetate in refluxing sodium 
ethoxide for 3 hours in 95% yield as reported before [20]. Alkylation of mercaptopyrimidine 
1 was carried out by a standard alkylation method using sodium hydroxide solution (2N) as 
base at room temperature [20].    Design, Synthesis and Biological Evaluation of Novel Pyrimido[4,5-d]pyrimidine CDK2 Inhibitors …  435 
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To facilitate the synthetic pathways, we prepared the guanidine derivatives 5a,b  by 
reaction of isothiurinium HCl with sulfadimidine and 1-(4-aminophenyl)-3-phenylthiourea, 
which  were  prepared  by the  reaction of 4-nitroaniline with phenylisothiocyanate [21] 
followed by the reduction of the thiourea derivative with zinc and ammonium formate in 
ethanol at reflux. The base was obtained by trituration with NaHCO3 solution (Scheme 2).  
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Sch. 2.   Reagents and conditions (i) KOH, EtOH, r.t.; (ii) MeOH, Zn, HCOONH4;  
(iii) EtOH, reflux 16h. 
As a new modification of the Biginelli reaction, we synthesized compounds of type 6a–d by 
the reaction of aminopyrimidone  2  with aldehydes and guanidine derivatives 5a,b  in 
refluxing glacial acetic acid for 6–8 hours in up to 80% yield, which reacted with different 
amines in refluxing dimethyl formamide to afford the bicyclic products 7a–i (Scheme 3). 
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Biology 
Biochemical Assay 
CDK2, CDK4 and EGFR inhibitory activities of pyrimido[4,5-d]pyrimidines prepared above 
were shown in Table 1, together with those of  roscovitine [22, 23] and PYK2104 as 
reference compounds. CDK2 is one of CDK family protein which has a proline directed 
serine/ threonine kinase activity whereas EGFR belongs to receptor tyrosine kinase family. 
Compounds were further evaluated for their cell division inhibitory activities against 60 
human tumor cell lines. The newly synthesized compounds were tested against CDK4 
because CDK4 shares CDK2 the essential function of coupling the G1/S transition with 
mitosis [24]. 
Inhibitory activities are given  as IC50  values; for less active compounds percentage 
inhibition at a concentration of 10 μM is shown. It is noteworthy that most compounds with 
high activities towards CDK2 (IC50 < 1 μM) proved to be selective inhibitors. The data 
presented in Table 1 clearly showed that pyrimido[4,5-d]pyrimidine derivatives could be a 
good inhibitors of the CDK2, compound 7f is more active than roscovitine the reference 
with IC50 0.05. Two compounds 7e and 7a showed a very good inhibition with IC50 values 
0.25 and 0.31 µM respectively. Compound 7d had the least selectivity towards the CDK2 
inhibition and the other compounds showed moderate activity and selectivity. Compounds 
6d  and  7f  showed the best CDK4 activity with IC50  0.66 and 0.86 respectively. Four 
compounds 6a, 7c, 7h and 7i showed no activity on CDK4. The other compounds showed 
moderate activity and selectivity except compounds 7d  and  7g  which had very poor 
activity. Finally, most compounds did not show any significant EGFR inhibitory activity, 
indicating a good selectivity in the situation of protein kinase inhibitors. 
According to the data in table 1 we can say that the structural postulates for potential 
pyrimido[4,5-d]pyrimidine inhibitors derived from Roscovitine- or ATP-type binding model 
are proved to be correct. 
Cytotoxicity assay 
Evaluation of anti-cancer activities on pyrimido[4,5-d]pyrimidine derivatives were 
performed at the National Cancer Institute (NCI) USA. First the newly synthesized 
compounds have been evaluated in primary anti-cancer assay at 10
−5M concentration 
against 60 human tumor cell lines then the active compounds were tested at 5 different 
concentrations against the same 60 human tumor cell lines. The biological data for the 
newly synthesized compounds are compiled in table 2 
By the analysis of the data in table 2 we found that all the tested compounds showed 
different activities on the different cell lines. Compounds 6a, 6c and 7e had cell death 
activities on Non-small cell lung cancer (HOP-92) 102.6% inhibition, Renal cancer (RXF 
393) 124% and 112.9% inhibition respectively. Compounds 7c and 7d showed very high 
growth inhibitions on Melanoma (UACC-257) 71.36% and 79.49 growth inhibition % 
respectively. Compounds 7a, 7b, 7c, 7f and 7h showed high growth inhibitions ranging 
from 50 to 70 % on Non-small cell lung cancer, Ovarian cancer, Leukemia, and Melanoma. 
The rest of compounds and some of the aforementioned compounds had moderate to low 
growth inhibition ranging from 20 to 50 % in different tumor cell lines. 438  S. M. El-Moghazy et al.:   
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It seems that there is no good correlation between in-vitro CDK2 inhibitory activity and cell 
growth inhibition activity among some tested compounds e.g. compound 7f is the most 
active inhibitor against kinases but it does not seem to be the most potent against cell 
lines. Currently the reason is not clear but it may be due to different abilities to internalize 
inside cells. 
Conclusions  
All the biological results were complied with the molecular modeling studies to a 
considerable extent. The experimental activity of some compounds was found to be 
different from the expected theoretical values, some compounds showed high theoretical 
value while they had moderate to low biological results with respect to the other 
compounds, which can be explained by the conformational analysis of the synthesized 
compounds or the difficulty in cell permeability. 
Tab. 1.   IC50 Values for the newly synthesized compounds as CDK inhibitors. 
Cpd. 
IC50(μM)
a 
CDK2/CyclinA  CDK4/CyclinD  EGFR 
6a  5.0  >10  9.3 
6b  2.80  2.14  5.5 
6c  1.50  3.11  >10 
6d  2.50  0.66  7.8 
7a  0.31  3.33  >10 
7b  0.86  4.85  >10 
7c  2.60  >10  6.6 
7d  >10  6.88  >10 
7e  0. 25  2.55  4.9 
7f  0.05  0.86  >10 
7g  6.5  5.21  7.3 
7h  6.0  >10  >10 
7i  >10  >10  8.1 
Roscovitine  0.5  –  – 
PYK2104  –  –  0.0008 
a At least two independent experiments were performed for each 
compound in order to determine IC50 in replicates and potency is 
expressed by the mean of IC50 values obtained by nonlinear regression 
analysis. Coefficient of variance /SD/ mean) ranges from 10 to 24%. 
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Tab. 2.   Primary anti-cancer assay of the new compounds (Growth Inhibition %) 
Panel line 
Cpd.
a 
Cells 
6a  6b  6c  6d  7a  7b  7c 
Non-Small Cell  
Lung Cancer 
A549/ATCC      42.13  21.19  58.41    64.44 
EKVX          36.79  28.5   
HOP-92  102.6      26.97    20.79   
Breast Cancer 
BT-549    29.05           
HS 578T            33.65   
MCF7            43.46   
MDA-MB-
231/ATCC      23.08      31.53   
T-47D  26.93            23.41 
Ovarian Cancer  IGROV1    30.74  34.33    29.74    61.71 
OVCAR-8    38.74           
Leukemia 
HL-60(TB)      23.97      24.48  23.13 
K-562    20.12  27.89      53.68  32.76 
MOLT-4        43.38  36.7  32.94  22.58 
RPMI-8226      32.99    22.62  50.23  50.67 
Renal Cancer  RXF 393  33.82    124.01         
UO-31          21.35    39.48 
Melanoma  UACC-257      25.23    60.26    71.36 
CNS Cancer  SF-539      36.74      42.05   
SNB-75              43.14 
Panel line 
Cpd.
a 
Cells 
7d  7e  7f  7g  7h  7i   
Non-Small Cell  
Lung Cancer 
A549/ATCC  44.71    51.98      39.12   
EKVX               
HOP-92    39.6  34.82  29.05  24.32     
Breast Cancer 
BT-549          38.98     
HS 578T    32.93        26.23   
MCF7        33.32       
MDA-MB-
231/ATCC  21.44    30.36         
T-47D            30.15   
Ovarian Cancer  IGROV1  39.7    54.43    28.01     
OVCAR-8  26.8    21.76    50.24     
Leukemia 
HL-60(TB)    42.9  21.6    28.97     
K-562    28.19  26.48  20.11       
MOLT-4    35.05      20.8     
RPMI-8226  30.45  42.84  58.92    52.49     
Renal Cancer  RXF 393    112.9           
UO-31  30.71    40.29    21.08  30.55   
Melanoma  UACC-257  79.49    57.86  32.66       
CNS Cancer  SF-539    23.47           
SNB-75      28.53      23.21   
The newly synthesized compounds were evaluated in primary anti-cancer assay at 10
−5M 
concentration against 60 human tumors cell line then the active compounds were tested at 5 different 
concentrations against the same 60 human tumor cell lines. 440  S. M. El-Moghazy et al.:   
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Experimental 
Chemistry 
All melting points were uncorrected and determined by the open capillary method using a 
Gallenkamp melting point apparatus. IR spectra were recorded (KBr) on a Pye-Unicam 
SP-883 Perkin Elmer spectrophotometer. 
1HNMR spectra were recorded on a varian EM 
400–600 MHz  spectrometer using DMSO-d6  as a solvent and TMS as an internal 
reference, chemical shifts are expressed in δ units (ppm). Mass spectra were recorded 
with a mass spectrometer MS9 (AEI) 70 ev. All the analytical data were obtained from 
Microanalytical Data Unit at Cairo University and Toledo University. All the results were 
within an acceptable range.  
6-Amino-2-sulfanylpyrimidin-4(3H)-one (1) 
Compound 1 was prepared according to a literature method [20]. 
6-Amino-2-(benzylsulfanyl)pyrimidin-4(3H)-one (2) 
Method A 
To a solution of compound 1 (14.3 g, 0.1 mol) in a mixture of dimethyl sulfoxide (20 mL) 
and sodium hydroxide 2N (5 mL), Benzyl chloride (11.6 mL, 0.1 mol) was added drop-wise 
with stirring for one and half hour. The resulting mixture was poured onto cold water 
(200 mL), acidified by glacial acetic acid then filtered using vacuum filtration, air dried and 
recrystallized from alcohol. 
Method B 
To a solution of compound 1 (14.3 g, 0.1 mol) in a mixture of dimethyl formamide (20 mL), 
and potassium carbonate (55.3 g, 0.4 mol), Benzyl chloride (11.6 mL, 0.1mol) was added 
drop-wise with stirring overnight. The resulting reaction mixture was poured onto cold 
water (200 mL), acidified by glacial acetic acid then filtered using vacuum filtration, dried in 
air and recrystallized from alcohol. 
Yellowish white crystals (95% yield); m.p. 122–124 °C; 
1HNMR (DMSO-d6): δ ppm 11.1 (s, 
1H, NH), 8.5 (s, 2H, NH2), 7.5–7.3 (m, 5H, Ar-H), 6.6 (s, 1H, H5), 4.5 (s, 2H, SCH2). MS 
m/z: 233.3 (M
+). Anal. Calcd for C11H11N3OS: C, 56.63; H, 4.75; N, 18.01 Found: C, 56.48; 
H, 4.73;N. 17.91. 
1-(4-Nitrophenyl)-3-phenylthiourea (3) 
To a solution of 4-nitroaniline (1.4 g, 0.01 mol) in ethanol (20 mL) was added an equimolar 
amount of phenylisothiocyanate (1.35 g, 0.01 mol) then Potassium hydroxide (1.7g, 0.03 
mol) was added. The reaction mixture was stirred for 4h at R. T. then the separated solid 
product was filtered off, dried, and recrystallized from ethanol to give compound 3. 
Yellow crystals (94% yield); m.p. 118–120 °C; 
1HNMR (DMSO-d6): δ ppm 12.4 (s, 1H, SH), 
9.5 (s, 2H, 2NH), 8.2–8.0 (m, 2H, Ar-H), 7.4–7.2 (m, 5H, Ar-H), 7.0–6.8 (m, 2H, Ar-H). MS 
m/z: 273 (M
+). Anal. Calcd for C13H11N3O2S: C, 57.13; H, 4.06; N, 15.37 Found: C, 57.48; 
H, 4.13; N. 15.71. 
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1-(4-Aminophenyl)-3-phenylthiourea (4) 
A suspension of nitrophenylthiourea derivative 3 (1.4 g, 5 mmol) and Zn dust (0.4 g, 6 
mmol) in methanol (15 ml) was stirred with ammonium formate (0.5 g) at room 
temperature. After completion of the reaction (monitored by TLC), the mixture was filtered 
off. The organic layer was evaporated and the residue dissolved in CHCl3 and washed 
with saturated NaCl to remove ammonium formate. The organic layer upon evaporation 
gave the desired amino derivative 4. 
Yellowish white crystals (86% yield); m.p. 134–136 °C; 
1HNMR (DMSO-d6): δ ppm 12.1 (s, 
1H, SH), 8.9 (s, 2H, 2NH), 7.5–7.1 (m, 5H, Ar-H), 6.9–6.7 (m, 4H, Ar-H), 6.4 (s, 2H, NH2). 
MS m/z: 243 (M
+). Anal. Calcd for C13H13N3S: C, 64.17; H, 5.39; N, 17.27 Found: C, 64.48; 
H, 5.13; N. 17.71. 
Arylguanidine derivatives (5) 
A mixture of benzyl isothiourinium hydrochloride (10.2 g, 0.05 mol) and the appropriate 
amine (0.06 mol) in absolute alcohol (200 mL) was refluxed for 16 hours. The reaction 
mixture was evaporated  to dryness in a  water bath and the resulting precipitate was 
triturated with NaHCO3  solution (100 mL, 2%). The resulting precipitate was filtered, 
washed thoroughly with water, air dried and used without further purification for the next 
step.  
1-(4-Guanidinophenyl)-3-phenylthiourea (5a) 
Brown crystals (89% yield); m.p. 140–142 °C; 
1HNMR (DMSO-d6): δ ppm 9.1 (s, 2H, 2NH), 
7.6–7.4 (m, 4H, Ar-H), 7.3–7.2 (m, 5H, Ar-H), 7.1 (s, 1H, NH), 6.9 (s, 1H, NH), 6.7 (s, 2H, 
NH2). MS m/z: 287 (M
+2). Anal. Calcd for C14H15N5S: C, 58.92; H, 5.30; N. 24.54 Found: C, 
59.48; H, 4.73;N. 23.71. 
N-(4,6-Dimethylpyrimidin-2-yl)-4-guanidinobenzenesulfonamide (5b) 
White crystals (79% yield); m.p. 220–222 °C; 
1HNMR (DMSO-d6) :  δ  p p m  8  ( s ,  1 H ,  
SO2NH), 7.8–7.7 (dd, 2H, Ar-H), 7.4–7.3 (dd, 2H, Ar-H), 7.1 (s, 1H, NH), 7 (s, 1H, H5-
pyrimidine), 6.8 (s, 1H, NH), 6.7 (s, 2H, NH2), 2.1 (s, 6H, 2CH3). MS m/z: 321 (M
+1). Anal. 
Calcd for C13H16N6O2S: C, 48.74; H, 5.03; N, 26.23 Found: C, 49.48; H, 4.73; N, 25.41. 
2-(Benzylsulfanyl)-5-aryl-7-(arylamino)pyrimido[4,5-d]pyrimidin-4(3H)-ones (6) 
A solution of compound 5a,b (0.05 mol) and the appropriate aldehyde in glacial acetic acid 
was refluxed for an hour, and then compound 2 (11.7 g, 0.05 mol) was added and refluxed 
for another 10 hours. The reaction mixture was concentrated to half volume, cooled, 
poured on cold water (500 mL), filtered using vacuum filtration, air dried and recrystallized 
from DMF-H2O. 
1-(4-{[7-(Benzylsulfanyl)-4-(2,4-dihydroxyphenyl)-5-oxo-5,6-dihydro-
pyrimido[4,5-d]pyrimidin-2-yl]amino}phenyl)-3-phenylthiourea (6a) 
Brown red crystals (80% yield); m.p. > 300 °C; 
1HNMR (DMSO-d6): δ ppm 11.9 (s,1H, NH 
pyrimidone), 8.6 (s, 2H, NHCSNH), 8.4 (s, 2H, 2OH), 8.3 (s, 1H, NH), 7.4–6.8 (m, 17H, Ar-
H), 3.7 (s, 2H, SCH2). 
13C NMR (DMSO-d6, 100 MHz): δ ppm 38, 104, 106.1, 112.2, 116.3, 
123.3, 128.5, 130.6, 132.2, 133.4, 135.8, 137.1, 138.6, 140.1, 142.5, 144.4, 145.9, 146.8, 442  S. M. El-Moghazy et al.:   
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150.1, 160.2, 162.4, 164.4, 165.8, 167.7, 176.2, 181.8. MS m/z: 620 (M
+1). Anal. Calcd for 
C32H25N7O3S2: C, 62.02; H, 4.07; N. 15.82 Found: C, 62.48; H, 3.73; N. 15.51. 
4-{[7-(Benzylsulfanyl)-4-(2,4-dihydroxyphenyl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyrimidin-
2-yl]amino}-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide (6b) 
Orange red crystals (75% yield); m.p. > 300 °C; 
1HNMR (DMSO-d6): δ ppm 11.5 (s, 1H, 
NH pyrimidone), 8.9 (s, 2H, 2OH), 8.7 (s, 2H, 2NH), 7.6–7.0 (m, 9H, Ar-H), 6.9 (s, 1H, H5 
pyrimidine), 4.4 (s, 2H, SCH2), 2.2 (s, 6H, 2CH3). MS m/z: 656 (M
+1).  Anal. Calcd for 
C31H26N8O5S2: C, 56.87; H, 4.00; N. 17.11. Found: C, 56.11; H, 4.15; N. 16.89. 
1-(4-{[7-(Benzylsulfanyl)-4-methyl-5-oxo-5,6-dihydropyrimido[4,5-d]pyrimidin-2-yl]amino}-
phenyl)-3-phenylthiourea (6c)  
Purple crystals (80% yield); m.p. > 300 °C; 
1HNMR (DMSO-d6): δ ppm 12.3 (s,1H, NH 
pyrimidone), 9.2 (s, 2H, NHCSNH), 8.8 (s, 1H, NH), 7.8–7.1 (m, 14H, Ar-H), 3.9 (s, 2H, 
SCH2), 2.5 (s, 3H, CH3). MS m/z: 525 (M
+). Anal. Calcd for C27H23N7OS2: C, 61.69; H, 
4.41; N.18.65. Found: C, 60.73; H, 4.34; N. 19.02. 
4-{[7-(Benzylsulfanyl)-4-methyl-5-oxo-5,6-dihydropyrimido[4,5-d]pyrimidin-2-yl]amino}-
N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide (6d) 
Pale yellow crystals (70% yield); m.p. > 300 °C; 
1HNMR (DMSO-d6): δ ppm 11.1 (s, 1H, 
NH pyrimidone), 8.9 (s, 2H, 2NH), 7.8–7.3 (m, 9H, Ar-H), 7.2 (s, 1H, H5 pyrimidine), 4.0 (s, 
2H, SCH2), 2.6 (s, 3H, CH3), 2.1 (s, 6H, 2CH3). 
13C NMR (DMSO-d6, 100 MHz): δ ppm 
20.5, 23.8, 36.9, 108.2, 115.2, 123.5, 129.1, 130.9, 132.5, 135.3, 139.1, 140.2, 145.7, 
152.2, 155.1, 163.1, 165.9, 167.8, 169.3, 172.5. Anal. Calcd for C26H24N8O3S2: C, 55.7; H, 
4.31; N. 19.99. Found: C, 54.82; H, 4.19; N. 20.27. 
7-(Alkyl/Arylamino)-5-alkyl-2-(arylamino)pyrimido[4,5-d]pyrimidin-4(3H)-one (7)  
To a solution of Compound 6a–d (5 mmol) in a mixture of dimethyl formamide (10 mL) and 
glacial acetic acid (5 mL), the appropriate amine (5  mmol) was added. The reaction 
mixture was refluxed for 8 hours, cooled and poured onto cold water (200 mL). The 
resulting precipitate was collected, air dried and recrystallized from acetic acid-H20. 
1-(4-{[7-(Benzylamino)-4-(2,4-dihydroxyphenyl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyrimidin-
2-yl]amino}phenyl)-3-phenylthiourea (7a) 
Brown red crystals (60% yield); m.p. > 300 °C; 
1HNMR (DMSO-d6): δ ppm 9.9 (s, 1H, NH 
pyrimidone), 8.6 (s, 2H, 2OH), 8.2 (s, 2H, HNCSNH), 6.8–7.3 (m, 17H, Ar-H), 6.9 (s, 1H, 
NH Benzyl), 6.5 (s, 1H, NH), 3.8 (s, 2H, PhCH2). 
13C NMR (DMSO-d6, 100 MHz): δ ppm 
40.3, 98.9, 101.6, 106.4, 110.7, 117.5, 120.8, 123.7, 124.9, 125.5, 127.6, 128.9, 130.1, 
131.9, 132.7, 135.5, 136.4, 139.1, 152.1, 155.9, 158.5, 160.3, 161.6, 163.8, 171.4, 181.8. 
IR (KBr) cm
−1: 3296, 3182, 3057, 2922, 1627, 1593. MS m/z: 604 (M
+1). Anal. Calcd for 
C32H26N8O3S: C, 63.77; H, 4.35; N, 18.59. Found: C, 64.24; H, 4.12; N, 18.13.  
1-(4-{[7-(Benzylamino)-4-methyl-5-oxo-5,6-dihydropyrimido[4,5-d]pyrimidin-2-yl]amino}-
phenyl)-3-phenylthiourea (7b) 
Purple crystals (65% yield); m.p. > 300 °C; 
1HNMR (DMSO-d6): δ ppm 10.1 (s, 1H, NH 
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1H, NHPh), 4.3 (s, 2H, PhCH2), 2.3 (s, 3H, CH3). IR (KBr) cm
−1: 3296, 3182, 3055, 2924, 
1631, 1593. Anal. Calcd for C27H24N8OS: C, 63.76; H, 4.76; N, 22.03. Found: C, 63.64; H, 
4.31; N, 22.84. 
4-{[7-(Benzylamino)-4-methyl-5-oxo-5,6-dihydropyrimido[4,5-d]pyrimidin-2-yl]amino}-
N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide (7c) 
Yellow crystals (50% yield); m.p. > 300 °C; 
1HNMR (DMSO-d6): δ ppm 11.5 (s, 1H, NH 
pyrimidone), 7.4 (s, 1H, NH Benzyl), 7.3–7.1 (m, 9H, Ar-H), 6.5 (s, 1H, H5 pyrimidine), 4.9 
(s, 1H, SO2NH), 4.3 (s, 2H, PhCH2), 2.8 (s, 3H, CH3), 2.2 (s, 6H, 2CH3). IR (KBr) cm
−1: 
3311, 3199, 3026, 2922, 1630, 1570. Anal. Calcd for C32H26N8O3S: C, 57.45; H, 4.64; N, 
23.19. Found: C, 57.82; H, 4.38; N, 23.56.  
1-[4-({7-[(3-Chlorophenyl)amino]-4-(2,4-dihydroxyphenyl)-5-oxo-5,6-dihydro-
pyrimido[4,5-d]pyrimidin-2-yl}amino)phenyl]-3-phenylthiourea (7d) 
Brown red crystals (55% yield); m.p. > 300 °C; 
1HNMR (DMSO-d6): δ ppm 11.2 (s, 1H, NH 
pyrimidone), 8.8 (s, 2H, NHCSNH), 8.2 (s, 2H, 2OH), 8.1 (s, 2H, 2NH), 7.3–-6.9 (m, 16H, 
Ar-H). IR (KBr) cm
−1: 3360, 3340, 3260, 3220, 3026, 2970, 1640, 1590. MS m/z: 525 (M
+1). 
Anal. Calcd for C31H23ClN8O3S: C, 59.76; H, 3.72; N, 17.98. Found: C, 60.03; H, 3.92; N, 
18.35.  
1-[4-({7-[(3-Chlorophenyl)amino]-4-methyl-5-oxo-5,6-dihydropyrimido[4,5-d]pyrimidin-
2-yl}amino)phenyl]-3-phenylthiourea (7e) 
Purple crystals (55% yield); m.p. > 300 °C; 
1HNMR (DMSO-d6): δ ppm 11.5 (s, 1H, NH 
pyrimidone), 8.9 (s, 2H, NHCSNH), 8.5 (s, 2H, 2NH), 7.3–6.9 (m, 13H, Ar-H), 2.2 (s, 3H, 
CH3).
13C NMR (DMSO-d6,  100  MHz):  δ  ppm  19.8,  102.6,  120.1,  121.9, 122.4, 123.1, 
125.4, 126.9, 127.7, 130.1, 131.8, 132.5, 135.8, 140.1, 141.6, 142.9, 144.1, 160.3, 164.2, 
167.9, 172.2, 180.8. IR (KBr) cm
−1: 3300, 3197, 3055, 2924, 1631, 1593. MS m\z: 530 
(M
+1). Anal. Calcd for C26H21ClN8OS: C 59.03; H, 4.00; N, 21.18. Found: C, 59.64; H, 3.89; 
N, 21.34.  
4-({7-[(3-Chlorophenyl)amino]-4-methyl-5-oxo-5,6-dihydropyrimido[4,5-d]pyrimidin-
2-yl}amino)-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide (7f) 
Yellow crystals (65% yield); m.p. > 300 °C; 
1HNMR (DMSO-d6): δ ppm 11.6 (s, 1H, NH 
pyrimidone), 8.8 (s, 1H, SO2NH), 8.4 (s, 2H, 2NH), 7.4–7.2 (m, 8H, Ar-H), 6.8 (s, 1H, H5 
Pyrimidine), 2.7 (s, 3H, CH3), 2.1(s, 6H, 2CH3). IR (KBr) cm
−1: 3448, 3142, 3026, 2924, 
1620, 1570. Anal. Calcd for C25H22ClN9O3S: C, 53.24; H, 3.93; N, 22.35. Found: C, 53.19; 
H, 3.82; N, 22.74.  
4-{[5-(2,4-Dihydroxyphenyl)-4-oxo-7-({4-[(phenylcarbamothioyl)amino]phenyl}amino)-
3,4-dihydropyrimido[4,5-d]pyrimidin-2-yl]amino}benzenesulfonic acid (7g) 
Reddish brown crystals (62% yield); m.p. > 300 °C; IR (KBr) cm
−1: 3296, 3140, 3057, 
2922, 1629, 1593; 
1HNMR (DMSO-d6): δ ppm 12.1 (s, 1H, NH pyrimidone), 11.1 (s, 1H, 
OH), 10.5 (br, 4H, NH or SH), 10.2 (s,2H,2OH), 6.9–7.8 (m, 16H, Ar-H); MS m/z: 669 (M
+). 
Anal. Calcd for C31H24N8O6S2: C, 55.68; H, 3.62; N, 16.76. Found: C, 56.03; H, 3.74; N, 
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4-{[5-Methyl-4-oxo-7-({4-[(phenylcarbamothioyl)amino]phenyl}amino)-
3,4-dihydropyrimido[4,5-d]pyrimidin-2-yl]amino}benzenesulfonic acid (7h) 
Purple crystals (60% yield); m.p. > 300 °C; IR (KBr) cm
−1: 3311, 3199, 3026, 2922, 1630, 
1570; 
1HNMR (DMSO-d6): δ ppm 11.8 (s, 1H, NH pyrimidone), 11.0 (s, 1H, OH), 10.8 (br, 
4H, NH or SH), 7.2–8.1 (m, 13H, Ar-H), 2.8 (s, 3H, CH3); MS m/z: 575 (M
+1). Anal. Calcd 
for C26H22N8O4S2: C, 54.34; H, 3.86; N, 19.50. Found: C, 54.67; H, 3.34; N, 20.11. 
4-{[7-({4-[(4,6-Dimethylpyrimidin-2-yl)sulfamoyl]phenyl}amino)-5-methyl-4-oxo-3,4-dihydro-
pyrimido[4,5-d]pyrimidin-2-yl]amino}benzenesulfonic acid (7i) 
Purple crystals (65% yield); m.p. > 300 °C; 
1HNMR (DMSO-d6): δ ppm 12.1 (s, 1H, NH 
pyrimidone), 10.2 (s, 1H, SO2NH), 10.1 (s, 2H, 2NH), 10.0 (s, 1H, OH), 7.8–7.3 (m, 8H, Ar-
H), 7.1 (s, 1H, H5 Pyrimidine), 2.6 (s, 3H, CH3), 2.2 (s, 6H, 2CH3). 
13C NMR (DMSO-d6, 
100  MHz):  δ  ppm  20.6,  22.5,  102.6,  110.2,  118.3,  120.5,  124.6,  125.6,  134.1,  138.3, 
140.2, 142.6, 147.6, 150.1, 158.7, 160.4, 162.9, 165.3, 170.1. MS m/z: 6115 (M
+1). Anal. 
Calcd for C25H23N9O6S2: C, 49.25; H, 3.80; N, 20.68. Found: C, 49.74; H, 3.98; N, 21.21. 
Biological Methods 
Enzymatic activity inhibition assay 
The inhibition studies of cell cycle dependent kinase 2 were performed for the synthesized 
compounds along with roscovitine as reference compound. We synthesized roscovitine 
according to reported method [25]. CDK2/cyclinA enzyme was purified from infected sf21 
insect cells. For baculoviral  overexpression of proteins, we sub-cloned human CDK2 
c-DNA tagged by hexa-histidine on its N-terminal and human cyclinA c-DNA into pBacPak 
8 expression vector, respectively. Baculovirus which carries each gene was generated 
using baculovirus generating kit. CDK2/cyclinA enzyme was purified using Ni
+2-affinity 
resin from sf21 insect cell culture into which CDK2 and cyclin A carrying baculoviruses 
were cotransfected. Enzyme assays were done in 20 mL of 50 mMTris-HCl containing 10 
mM ATP, 0.2 mCi of gamma-P
32 ATP, 10 mM MgCl2, 5 mM DTT and 4 mg of histone H1 
was used as a substrate. The reaction was continued for 10 min in the presence of 
inhibitors and stopped by adding 10 mL of 30% phosphoric acid. The stopped mixtures 
were spotted onto P81 paper and were washed with 10 mM Tris-HCl (pH 8.0) containing 
0.1 M NaCl five times. The radioactivity of each spot was quantified with BAS imager. The 
inhibition studies of human EGFR tyrosine kinase activities were done using C-terminal 
human EGFR tyrosine kinase domain as described previously  [26]. PYK2104 was 
synthesized as reported and used as a reference compound [26]. The concentration of 
inhibitor that gives 50% inhibition was designated as IC50 value. 
Measurement of potential cytotoxicity 
The cytotoxic activity was measured in vitro for the newly synthesized compounds using 
the SulfoRhodamine-B stain (SRB) assay using the method of Skehan [27]. Cells were 
plated in 96-multiwell microtiter plate (104 cells/ well) for 24 h before treatment with the 
compound(s) to allow attachment of cell to the wall of the plate. Tested compounds were 
dissolved in DMSO and diluted with saline to the appropriate volume. Triplicate wells were 
prepared for each individual dose. Monolayer cells were incubated with the compound(s) 
for 48 h at 37 °C and in atmosphere of 5% CO2. After 48 h, cells were fixed, washed, and 
stained for 30 min with 0.4% (wt/vol) with SRB dissolved in 1% acetic acid. Unbound dye   Design, Synthesis and Biological Evaluation of Novel Pyrimido[4,5-d]pyrimidine CDK2 Inhibitors …  445 
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was removed by four washes with 1% acetic acid, and attached stain was recovered with 
Tris-EDTA buffer. Color intensity was measured in an ELISA reader. The relation between 
surviving fraction and drug concentration is plotted to get the survival curve for tumor cell 
line after the specified time. 
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